# Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

Study · id `cardio:ct-nct01055912` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01055912](<https://clinicaltrials.gov/study/NCT01055912>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01055912

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

## Technical summary

Registry record NCT01055912. Randomized; triple masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 170 participants (enrolled count; ClinicalTrials.gov record NCT01055912, source copy `cardio:ctgov-nct01055912-2011-06-28`, retrieved 2026-10-26)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT01055912, source copy `cardio:ctgov-nct01055912-2011-06-28`, retrieved 2026-10-26)
- Primary completion: 2010-09 (actual) (ClinicalTrials.gov record NCT01055912, source copy `cardio:ctgov-nct01055912-2011-06-28`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: United States (ClinicalTrials.gov record NCT01055912, source copy `cardio:ctgov-nct01055912-2011-06-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01055912-2011-06-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure
- Condition: Congestive Heart Failure
- Intervention (Drug): Lixivaptan
- Intervention (Drug): Placebo
- Lead sponsor: CardioKine Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Cardiokine Biopharma, LLC
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study (`cardio:pubmed-22510424`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2a9630672b9590d6898b7cb74f1e5d985f5ec0739a05c68c0c75ed4728546b95
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
